Virtual Library

Start Your Search

Shengjie Sun



Author of

  • +

    P2.04 - Immuno-oncology (ID 167)

    • Event: WCLC 2019
    • Type: Poster Viewing in the Exhibit Hall
    • Track: Immuno-oncology
    • Presentations: 1
    • Now Available
    • Moderators:
    • Coordinates: 9/09/2019, 10:15 - 18:15, Exhibit Hall
    • +

      P2.04-17 - Immune Repertoire Is a Potential Predictive Biomarker for Evaluating the Efficacy of Mutant Neoantigen Specific T Cell Combined with PD1 Antibody (Now Available) (ID 555)

      10:15 - 18:15  |  Author(s): Shengjie Sun

      • Abstract
      • Slides

      Background

      The efficiency of PD1 monoclonal antibody used alone is not satisfactory. The therapeutic method of solid tumor with mutant neoantigen specific T (Nas-T) cell developed in this study is an adoptive cell therapy which is specific for each patient. Our previous research has proved that Nas-T can prolong patients' PFS with a good safety. We aim to further explore the effect of Nas-T on OS and to evaluate the characteristics of immune repertoire (IR) as a predictive biomarker.

      Method

      A total number of 12 patients with advanced solid tumors who failed after multiline treatments were recruited. They were treated with Nas-T cells, PD1 antibody and BSC; other 11 patients were treated with PD1 inhibitors and BSC as control. Peripheral blood was collected at baseline and per cycle (21-28d) respectively. Immunosequencing of the CDR3 regions of human TCRβ chains was used to detect IR. T-cell diversity and clonality for each IR was calculated. To quantitatively evaluate the consistency of the infused T-cell repertoires during the therapy, we adopted the Morisita overlap index (MOI), which considers the composition and the abundance of T-cell rearrangements. MOI ranges from 0 to 1, with 1 indicating identical TCR repertoires and 0 indicating completely distinct TCR repertoires between two samples.

      Result

      2.jpgUpdated data showed there was no statistical significance in OS (P>0.05), which may be related to the small sample size and short follow-up time. Compared to baseline, T-cell repertoire of NCB and DCB after 1st cycle displayed significant changes: Shannon 0.96 vs 1.20, P=0.004; Clonality 1.20 vs 0.64, P=0.003. Elevated Clonality may indicate expanded tumor-specific T-cells which could recognize mutant neoantigen specifically. MOI result for one patient, for example, exhibited a good consistency among each batch of infused Nas-T.

      Conclusion

      The combined immunotherapy of mutant Nas-T cell and PD1 antibody is more effective than PD1 antibody alone in prolonging PFS, but has no effect on OS. IR Clonality change shows its potential as a predictive biomarker.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.